|
|
|
| |
Advisory Board |
| |
|
 |
Prof. Michael Friedman |
| |
Prof. Friedman has extensive experience in the field of oral drug delivery as well as industrial pharmaceutics. He has published more than 130 papers and holds 24 U.S. patents to his credit. He was the inventor of the PerioChip, the flagship product of Perio Products, a multimillion-dollar drug delivery company that was eventually sold to a leading pharmaceutical manufacturer. Prof. Friedman is a faculty member at the Hebrew University of Jerusalem, the School of Pharmacy , and has held several prestigious positions as Academic Head of the School of Pharmacy and Chairman of its Department of Pharmaceutics. Professor Friedman also serves as a consultant for local and international pharmaceutical companies. |
| |
|
|
Prof. Amnon Hoffman |
| |
Prof. Hoffman is the Chairman of the Department of Pharmaceutics, and Head of the Clinical Pharmacy Program at the School of Pharmacy , Faculty of Medicine, the Hebrew University of Jerusalem. He has over 15 years experience in the field of pharmacokinetics and pharmacodynamics, specializing in the biological aspects of drug delivery systems. He is an Associate Professor at The Hebrew University of Jerusalem and has been teaching there since 1989. Prof. Hoffman founded the M.Sc. program in Clinical Pharmacy in 1990 and since then heads the Clinical Pharmacy Education Program. He is also the Chair of the Pharmaceutical Sciences and Clinical Pharmacy Education division at the University. Prof. Hoffman has published over 70 scientific papers. |
| |
|
|
Dr. Stanley Fahn, Neurologist |
| |
Dr. Fahn is the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University . He is the Scientific Director of the Parkinson's Disease Foundation. Dr. Fahn has twice served as Chairman of the Advisory Committee on Peripheral and Central Nervous System Drugs for the Food and Drug Administration. |
| |
|
|
Dr. Stephen Hanauer, Gastroenterologist |
| |
Dr. Hanauer , a recognized expert in inflammatory bowel disease, is Professor of Medicine and Clinical Pharmacology and Chief, Section of Gastroenterology and Nutrition at the University of Chicago . As past Chair of the GI Advisory Panel for the U.S. Food and Drug Administration, Dr. Hanauer authored the FDA's "Guidelines for Clinical Evaluation of Drugs for Patients with Inflammatory Bowel Disease". |
| |
|
|
Dr. Frank Lanza, Gastroenterologist |
| |
Dr. Lanza is Clinical Professor of Medicine in the Section of Gastroenterology at the Baylor College of Medicine in Houston , Texas . He is also the Director of the Houston Institute for Clinical Research in Houston . His primary research interest is injury to the GI tract from NSAIDs and other agents. He has published over 100 papers on this
and other subjects in peer-reviewed journals. He also maintains a small private consultation practice in Gastroenterology.
|
| |
|
|
Prof. Zamir Halpern Gastroenterologist |
| |
Prof. Halpern is Deputy Director of the Department of Gastroenterology and Hepatology at Tel Aviv University's Sourasky Medical Centre. He supervises major research programs and is Director of a large Gastroenterological Clinic. |
| |
|
|
Prof. Clive J Wilson |
| |
Prof. Wilson is an expert in the study of the behavior of drug dosage formulations in humans, particularly following delivery by the gastrointestinal tract. He is a specialist in the utilization of gamma scintigraphy and other imaging techniques in drug delivery research and the relationship between formulation characteristics and absorption in the human gastrointestinal tract. |
| |
|
|
Dr. Phil Katz, Gastroenterologist |
| |
Dr. Katz is the chairman of the Division of Gastroenterology and Nutrition at Albert Einstein Medical Center in Philadelphia. He is a recognized authority on esophageal disease whose primary research interests include all aspects of gastroesophageal reflux disease, nocturnal recovery of gastric acid secretion during proton pump inhibitor therapy, and esophageal pain perception. |
| |
|
|
Dr. David Rutta, Gastroenterologist |
| |
Dr. Rutta heads a large GI clinic in the Northeast United States that performs thousands of GI procedures annually.
He runs clinical research programs for major Pharma companies.
|
| |
|
|
Dr. Ron Filler, toxicologist |
| |
Dr. Filler is a Toxicologist with more than 20 years of safety assessment experience in nonclinical toxicology/safety pharmacology within the pharmaceutical and biopharmaceutical industries.
He has experience in CNS therapies, antivirals, antibiotics, cardiovascular diseases, antihypertensives, anti-diabetic therapies, oncology and osteoporotic agents, as well as regulatory experience with medical and in vitro diagnostic devices. |
| |
|
|
Dr. Mario Guralnik, Clinical and Regulatory consultant |
| |
Dr. Guralnik is the president of Synergy Research Inc, a professional independent clinical contract research organization specializing in clinical drug development.
He has over 25 years experience in drug development strategies, specializing in regulatory and clinical affairs. |
| |
|
|
Dr. Nick Fleischer, Regulatory consultant |
| |
Dr. Fleischer is Vice President, Clinical Pharmacology & Biopharmaceutics, THE WEINBERG GROUP INC. He formerly held several senior management positions at the FDA, the most recent being Director of the Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research (CDER). |
| |
|
 |
|
|
